Objectives Chorea, characterised by involuntary, irregular movements, is a rare neurological manifestation of antiphospholipid syndrome (APS). The specific clinical features remain unclear. This study ...

Objectives To compare two measures of systemic lupus erythematosus (SLE) response: the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and the Systemic Lupus ...

Objective We have developed a new conceptual model to characterise the signs and symptoms of SLE: the Type 1 and 2 SLE Model. Within the original model, Type 1 SLE consists of inflammatory ...

4 Department of Preventive Medicine, Feinberg School of Medicine, Chicago, Illinois, USA Background/objective Patients with systemic lupus erythematosus (SLE) are at increased risk for adverse ...

Objectives Based on clinical and laboratory indicators, this study aimed to establish a multiparametric nomogram to assess the risk of refractory cases of SLE-related thrombocytopenia (SLE-related TP) ...

Objective To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and lupus non-specific ...

Objective To determine frequency, demographic and treatment characteristics of patients with an overlapping second autoimmune illness (2nd AI). Methods We analysed two cohorts containing 897 patients ...

Background and aims Systemic lupus erythematosus (SLE) predominantly affects individuals at peak age of productivity, and medical costs negatively impact on personal, family and community resources.

Objectives In SLE, deregulation of haematopoiesis is characterised by inflammatory priming and myeloid skewing of haematopoietic stem and progenitor cells (HSPCs). We sought to investigate the role of ...

Background The short-term and long-term outcome of inflammatory neuropsychiatric SLE (NPSLE) with immunosuppressive treatment is largely unknown. We used clinical data from our tertiary referral ...

Objective To examine the efficacy and safety of telitacicept in the treatment of patients with SLE in everyday clinical practice. Methods Seventy-two patients with active SLE who received telitacicept ...